Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 update. The firm is “encouraged” by the company’s clinical development and the rest of its pipeline assets, pointing to a higher view on the odds of success for the rheumatoid arthritis program as a driver of its raised price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions
- AnaptysBio Reports Strong Progress in Clinical Trials
- AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst
- AnaptysBio reports Q4 EPS (72c), consensus ($1.70)